Clinical Trial Update: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluated IPP-201101 plus standard of care vs placebo in systemic lupus erythematosus; study completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• IPP-201101 (IPP-201101)

Snippet

Sponsor: ImmuPharma | Conditions: Lupus Erythematosus, Systemic | Phase 3 | Status: COMPLETED | Results posted: 2019-04-11